Janus Henderson Group’s Ibere Pharmaceuticals IBER Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-52,917
Closed -$534K 2807
2022
Q4
$534K Sell
52,917
-52,917
-50% -$529K ﹤0.01% 1684
2022
Q3
$1.05M Buy
+105,834
New +$1.04M ﹤0.01% 1615

Janus Henderson Group's IBER Position: Q1 2023 in Review

Janus Henderson Group sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 52,917 shares — an estimated $534K sold.

Janus Henderson Group first reported a position in IBER in Q3 2022 and held it in 2 quarters. The position peaked at $1.05M in Q3 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

  • Janus Henderson Group reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Janus Henderson Group sold 52,917 Ibere Pharmaceuticals shares in Q1 2023, an estimated $534K.
  • Janus Henderson Group first reported a position in Ibere Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Janus Henderson Group's Ibere Pharmaceuticals position peaked at $1.05M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.